

DIASORIN SIGNES A 4 YEAR AGREEMENT WITH SEEGENE ON NUCLEIC ACID EXTRACTION INSTRUMENTS AND KITS

April 3, 2013 - Saluggia (VC) - **DiaSorin** (FTSE MIB:DIA) is pleased to announce that it has signed a new **4 year agreement with Seegene** (KOSDAQ: 096530), a global Korean leader of multiplex molecular diagnostics.

Under the OEM agreement, **DiaSorin will manufacture and supply nucleic acid extraction instruments and kits to Seegene** under the *Seeprep®* brand name.

The *Seeprep® 12 instrument* is based on DiaSorin's own compact bench top Nucleic extraction system. Seegene will provide the *Seeprep® 12 instrument* and *Seeprep® extraction kits*, also manufactured by DiaSorin, together with its own nucleic acid amplification systems and kits.

The agreement consistently pursues the strategy of DiaSorin to become an important worldwide player into the Molecular Diagnostics business, leveraging on its full offer either on instruments and on kits for the extraction of nucleic acids and their amplification and detection.

DiaSorin recently entered the molecular diagnostics arena with launch of its own LIAISON® IAM (available outside the US and Canada only) molecular analyzer which uses a novel development of the LAMP technology licensed from *Eiken Corporation*.

The **DiaSorin Q-LAMP™** technology provides real time, quantitative, multiplexed amplification of both DNA and RNA targets, for applications in **Infectious Diseases**.

The company is also developing a range of products for **Onco-Hematology** applications which promise to provide ultra rapid and very accurate results which will aid in the clinical decision making and treatment of patients with leukemia.

Mr. Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented *"I am pleased that Seegene and DiaSorin have agreed to a new supply contract which will see the relationship extended through to the end of 2017.*

Our companies had been in negotiation on a new contract since last June when we bought the Norwegian company NorDiag, specialized in the development and supply of systems and reagents for the extraction of nucleic acid and cell separation.

The agreement with Seegene proves our full commitment to the extraction business and its potential to become more relevant going forward, as well as our intention to be always an innovating company able to address new challenges into the IVD market”.

About DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Its line of products meets the clinical laboratory needs with flexibility in many clinical areas, such as infectious diseases, cardiac markers, bone metabolism, hepatitis and retrovirus, oncology and endocrinology.

Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market which identify DiaSorin Group as "the" in vitro diagnostics specialist.

About Seegene

Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies - ACP™, DPO™, READ, and qTOCE™ - are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene aims to become one of the top five global molecular diagnostics firms by 2015 and is actively pushing ahead with a series of promising licensing deals with global top-tier healthcare players to make its qTOCE™ technology become the new gold standard.

For additional information, please contact:

Riccardo Fava

External Relations Director - Head of IR and Media

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Margherita Sacerdoti

Investor Relations Specialist

Tel: +39.0161.487456

margherita.sacerdoti@diasorin.it